Zevra Therapeutics (ZVRA) Share-based Compensation (2014 - 2026)

Zevra Therapeutics has reported Share-based Compensation for 13 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation changed 0.32% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.6 million (down 20.61% YoY), and the FY2025 full-year result was $12.6 million, down 15.24% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.1 million, down from $4.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $6.1 million in Q3 2024, with the low at $911000.0 in Q3 2022.
• Historically, Share-based Compensation has averaged $2.3 million across 5 years, with a median of $2.1 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 374.84% — and 2025, when it sank 54.85%.
• Zevra Therapeutics' Share-based Compensation stood at $955000.0 in 2022, then surged by 54.14% to $1.5 million in 2023, then jumped by 172.96% to $4.0 million in 2024, then rose by 6.62% to $4.3 million in 2025, then retreated by 27.52% to $3.1 million in 2026.
• The last three Share-based Compensation figures came in at $3.1 million (Q1 2026), $4.3 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.